MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
LA JOLLA, Calif., April 07, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded…